Research Topics
Genomes and GenesSpecies | Moshe MittelmanSummaryCountry: Israel Publications
| Collaborators
|
Detail Information
Publications
The lower risk MDS patient at risk of rapid progressionMoshe Mittelman
Department of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel
Leuk Res 34:1551-5. 2010..In summary, some patients, classified as "low risk MDS" carry PPF. An appropriate therapeutic approach is indicated. Future updated classifications and prospective trials may lead to a better outcome...
[Residency: in the hospital or in the community?]Moshe Mittelman
Department of Medicine Tel Aviv Sourasky Medical Center Sackler Faculty of Medicine, Tel Aviv University
Harefuah 146:444-6, 501. 2007..The influence of such reform on the work in both the hospitals and the community is also discussed. It is notable that Nirel and colleagues should be congratulated for raising this serious question in the national medical debate...
Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelinesMoshe Mittelman
Department of Medicine, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
Isr Med Assoc J 10:374-6. 2008
Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studiesMoshe Mittelman
Department of Medicine B and The Hematology Service, Rabin Medical Center Hasharon Hospital, Petah Tikva, Israel
Eur J Haematol 72:155-65. 2004..Future trials should determine the role of Epo in myeloma and cancer treatment, besides clarifying concerns about the presence of Epo receptors on some tumor cells...
Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator?Sara Prutchi Sagiv
Department of Cell and Developmental Biology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Exp Hematol 36:1682-90. 2008..We thus focused on dendritic cells (DCs), the most potent antigen-presenting and T-cell-priming cells, as possible mediators of the immunomodulatory actions of EPO...
Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cellsLilach Lifshitz
Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel
Mol Immunol 46:713-21. 2009..Taken together, our data support the premise that DCs are direct targets of EPO, thereby providing an insight to the immunomodulatory functions of EPO...
Non-erythroid effects of erythropoietin: are neutrophils a target?Maayan Avneon
Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel
Leuk Res 33:1430-2. 2009..Hence, neutrophils are probably not mediators of the EPO immunological effects, although their counts may be affected by extreme EPO levels...
The implications of anemia in multiple myelomaMoshe Mittelman
Department of Medicine, Rabin Medical Center, Hasharon Hospital, Petah Tikva Sackler School of Medicine, Tel Aviv University, Israel
Clin Lymphoma 4:S23-9. 2003..This effect has been shown to be immune mediated. If these exciting data are confirmed in future clinical trials, this may have significant implications on the treatment of MM...
Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine modelsOdelia Katz
Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
J Endocrinol 205:87-95. 2010..Taken together, our data bear significant clinical implications of EPO treatment in the management of a wide range of metabolic diseases, thus adding an important novel therapeutic potential to this pleiotropic hormone...
Erythropoietin enhances immune responses in miceOdelia Katz
Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Eur J Immunol 37:1584-93. 2007..Epo-treated mice showed an enhanced immune response also to the clinically relevant hepatitis B surface antigen. These findings suggest a potential novel use of rHuEpo as an immunomodulator...
Erythropoietin in clinical practice: current use, effect on survival, and future directionsHoward S Oster
Department of Internal Medicine A, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Isr Med Assoc J 8:703-6. 2006....
Erythropoietin induced tumour mass reduction in murine lymphoproliferative modelsOdelia Katz
Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Acta Haematol 114:177-9. 2005
Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamideGideon Y Stein
Department of Internal Medicine B and the Hematology Unit, Rabin Medical Center, Golda-Hasharon Campus, Petah Tikva, Tel Aviv University, Sackler School of Medicine, Israel
Int J Hematol 80:94-6. 2004..This novel treatment modality for TTP has been described for only a few patients. A well-controlled clinical trial is warranted to determine the role and place of this therapeutic approach in the management of TTP...
A prospective national survey of management and clinical outcome of acute myocardial infarction in Israel, 2000Solomon Behar
Israel Center for Disease Control, Gertner Institute, Tel Hashomer, Israel
Isr Med Assoc J 5:249-54. 2003..Little information is available on the clinical practice and implementation of guidelines for treating acute myocardial infarction patients in Israel...
Erythropoietin and its receptor: signaling and clinical manifestationsJacob Cohen
Department of Cell Biology and Histology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
Isr Med Assoc J 4:1072-6. 2002
Platelet function and its clinical significance in the myelodysplastic syndromesAliza Zeidman
Department of Internal Medicine B, Rabin Medical Center, Golda Hasharon Campus, Petah Tikva, Sackler School of Medicine, Tel Aviv University, Israel
Hematol J 5:234-8. 2004..In the present study of 23 newly diagnosed MDS patients, PA abnormalities were relatively common, the BTs were usually normal, and bleedings were relatively uncommon and mild at platelet count between 70 and 397 x 109/l...
The management, early and one year outcome in hospitalized patients with heart failure: a national Heart Failure Survey in Israel--HFSIS 2003Moshe Garty
Recanati Center, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel
Isr Med Assoc J 9:227-33. 2007..Despite improved management of heart failure patients, their prognosis remains poor...
Anemia as a risk factor for ischemic heart diseaseAliza Zeidman
Department of Medicine B, Rabin Medical Center Golda Hasharon Campus, Petah Tiqva, Israel
Isr Med Assoc J 6:16-8. 2004..Based on knowledge of the physiologic role of oxygen delivery to the myocardium, anemia may be a cause of more severe cardiovascular diseases or a marker of other processes occurring in the body that induce more severe disease...
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBruce D Cheson
Department of Hematology/Oncology, Georgetown University Hospital, Washington, DC, USA
Blood 108:419-25. 2006..Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria...
Adherence to guidelines for patients hospitalized with heart failure: a nationwide surveyAlan B Jotkowitz
Department of Internal Medicine F, Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
Isr Med Assoc J 8:875-9. 2006..Despite significant advances in the therapy of heart failure, many patients still do not receive optimal treatment...
Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?Sara Prutchi-Sagiv
Cell and Developmental Biology, Rabin Medical Centre, Golda-Hasharon Campus, Petah-Tikya, Israel
Br J Haematol 135:660-72. 2006..It is expected that this would boost the immune system, consequently achieving an anti-myeloma function; affecting disease progression and improving the prognosis...
[Political issues in internal medicine in Europe. A position paper]Werner Bauer
Katedra i Klinika ChorĂ³b Wewnetrznych i Reumatologii Slaskiej Akademii Medycznej, Katowice
Pol Arch Med Wewn 115:612-6. 2006..Decision-makers in politics and hospitals, insurers, journalists, and the general public need a better understanding of what internal medicine can offer to the health care system and to the individual patient...
Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia modelsMarc Boogaerts
University Hospital Gasthuisberg, Leuven, Belgium
Oncology 69:22-30. 2005..Therefore, the role of epoetin may go well beyond that of increasing haemoglobin levels in anaemic patients, although additional studies are required to confirm these promising results...
Ocular expression of vascular cell adhesion molecule (VCAM-1) in 2-butoxyethanol-induced hemolysis and thrombosis in female ratsAbraham Nyska
Laboratory of Experimental Pathology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709 9998, USA
Exp Toxicol Pathol 55:231-6. 2003..No change in ICAM-1 or P-selectin expression was seen. This immunolabeling distribution suggests that VCAM-1 functions in the pathogenesis of BE-related thrombosis by promoting adhesion of erythrocytes to the endothelium...
A chemically induced rat model of hemolysis with disseminated thrombosisNathan Ezov
Harlan Biotech Israel Ltd, Rehovot, Israel
Cardiovasc Toxicol 2:181-94. 2002....
Late mortality and determinants in patients with heart failure and preserved systolic left ventricular function: the Israel Nationwide Heart Failure SurveyBasil S Lewis
Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center, Haifa, Israel
Isr Med Assoc J 9:234-8. 2007..Heart failure with preserved systolic left ventricular function is a major cause of cardiac disability...
